Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

On October 24, 2019 Asana BioSciences, a clinical stage biopharmaceutical company, reported that it will present ASN007 data on clinical safety and efficacy in solid tumor patients at the AACR (Free AACR Whitepaper)-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference to be held in Boston, MA on October 26-30, 2019 (Press release, Asana BioSciences, OCT 24, 2019, View Source [SID1234542500]). The Scientific Committee selected the ASN007 late breaking abstract submission as one of the top ten abstracts for this year’s program and invited presentation as a short-talk.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the presentation are as follows:

Abstract number:

666

Title:

Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors

Presenting Author:

Anthony W. Tolcher, MD FRCPC FACP

Director of Clinical Research, NEXT Oncology, San Antonio, TX

Session:

Spotlight on Proffered Papers

Date:

Tuesday, October 29, 2019

Time:

11:50 a.m.-12:30 p.m.

About ASN007

ASN007 is in Phase 1 clinical development. It is a potent inhibitor of the extracellular-signal-regulated kinases ERK1 and ERK2, which are key players in the RAS/RAF/MEK/ERK (MAPK) signaling pathway. ASN007 shows activity in KRAS-driven models, irrespective of subtype mutation, and BRAF models, including RAF/MEK inhibitor-resistant melanoma. ASN007 has a long target residence time and shows activity in preclinical models using an intermittent dosing schedule. ASN007 is being evaluated in patients with advanced solid tumors, including BRAF- and KRAS-mutant cancers (NCT03415126). The once-weekly maximum tolerated dose is determined and selected for the ongoing dose expansion.